

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63

October 18, 2021

ISSUE No.
1635

IN THIS ISSUE

Booster Dose of the Pfizer/BioNTech COVID-19 Vaccine (*Comirnaty*)p 161

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63 (Issue 1635)

October 18, 2021

Take CME Exams

▶ **Booster Dose of the Pfizer/BioNTech COVID-19 Vaccine (*Comirnaty*)**

On September 22, on the advice of its Vaccines and Related Biologic Products Advisory Committee, the FDA expanded the Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine (*Comirnaty*) to include administration of a booster dose ≥ 6 months after a 2-dose primary series in adults who are ≥ 65 years old or at high risk for severe COVID-19 because of an underlying medical condition or frequent institutional or occupational exposure to SARS-CoV-2 (see Table 1).¹ The FDA Advisory Committee recommended against authorization of a booster dose of *Comirnaty* for all persons ≥ 16 years old, citing a lack of adequate data.

ACIP – The Advisory Committee on Immunization Practices (ACIP) recommended to the CDC that booster doses of *Comirnaty* be administered to persons who are ≥ 65 years old, adult residents of long-term care facilities, and persons aged 50-64 years who have an underlying medical condition. The ACIP also recommended that booster doses be considered for younger adults with underlying medical conditions, but advised against their use on the basis of institutional or occupational exposure to SARS-CoV-2.

CDC – The CDC, which regulates US public vaccination programs, accepted most of the ACIP's recommendations, but stated that booster doses may indeed be considered for adults 18-64 years old who are at increased risk for severe COVID-19 because of frequent institutional or occupational exposure to SARS-CoV-2 (see Table 2).²

DOSAGE AND ADMINISTRATION – The booster dose of *Comirnaty* is the same as the dose for primary immunization (30 mcg IM). A single booster dose may be given ≥ 6 months after completion of a 2-dose primary series.³

CLINICAL STUDIES – Expansion of the EUA to include booster doses was based on cohort data from the US and Israel and on the results of an immunogenicity study.

Table 1. FDA-Licensed and Authorized Uses of the Pfizer/BioNTech COVID-19 Vaccine (*Comirnaty*)

Full Licensure
▶ Two-dose primary series in persons ≥ 16 years old (at 0 and 3 weeks) ¹
Emergency Use Authorization (EUA)
▶ Two-dose primary series in adolescents 12-15 years old (at 0 and 3 weeks) ²
▶ Three-dose primary series in persons ≥ 12 years old who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent (first two doses at 0 and 3 weeks; third dose ≥ 4 weeks after the second) ³
▶ Third (booster) dose in persons who are ≥ 65 years old or at high risk for severe COVID-19 because of an underlying medical condition or frequent institutional or occupational exposure to SARS-CoV-2 (given ≥ 6 months after completion of a 2-dose primary series) ⁴

1. FDA News Release. FDA approves first COVID-19 vaccine. August 23, 2021. Available at: <https://bit.ly/2WicpXc>. Accessed September 30, 2021.
2. In brief: Pfizer/BioNTech COVID-19 vaccine authorized for adolescents 12-15 years old. Med Lett Drugs Ther 2021; 63:81.
3. In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons. Med Lett Drugs Ther 2021; 63:145.
4. FDA News Release. FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations. September 22, 2021. Available at: <https://bit.ly/3ilp0B1>. Accessed September 30, 2021.

Waning Immunity – In a retrospective cohort study of ~3.4 million persons ≥ 12 years old in the US, those who received two doses of *Comirnaty* were significantly less likely to be infected with SARS-CoV-2 than those who were not vaccinated, but the relative risk reduction associated with vaccination declined from 88% at ≤ 1 month to 47% at ≥ 5 months after the second dose. Vaccination was also associated with a lower risk of hospitalization due to COVID-19; the relative risk reduction did not change significantly over time (87% at ≤ 1 month; 88% at ≥ 5 months).⁴

In a study that examined positive PCR test results for SARS-CoV-2 infection in Israel over 3 weeks in July 2021, adults ≥ 60 years old who completed a 2-dose primary series of the Pfizer/BioNTech vaccine in the second half of January 2021 had a significantly higher rate of infection than those who completed their series in the second half of March 2021 (3.2 vs 1.6 cases/1000 persons). Similarly, adults ≥ 60 years old who completed their series in January had a significantly higher rate of severe COVID-19 than those who completed it in March (0.29 vs 0.15 cases/1000 persons).⁵

Table 2. CDC Recommendations for Booster Doses of the Pfizer/BioNTech COVID-19 Vaccine^{1,2}

- ▶ Persons ≥65 years old and residents in long-term care settings **should** receive a booster dose ≥6 months after completion of their 2-dose Pfizer/BioNTech primary series.³
- ▶ Persons aged 50-64 years with underlying medical conditions⁴ **should** receive a booster dose ≥6 months after completion of their 2-dose Pfizer/BioNTech primary series.³
- ▶ Persons aged 18-49 years with underlying medical conditions⁴ **may** receive a booster dose ≥6 months after completion of their 2-dose Pfizer/BioNTech primary series,³ based on their individual benefits and risks.
- ▶ Persons aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting **may** receive a booster dose ≥6 months after completion of their 2-dose Pfizer/BioNTech primary series,³ based on their individual benefits and risks.

1. CDC. CDC statement on ACIP booster recommendations. September 24, 2021. Available at: <https://bit.ly/3o8uS42>. Accessed September 30, 2021.
2. A booster dose is currently not recommended for persons vaccinated with the Moderna or Johnson & Johnson vaccine.
3. A booster dose is currently not recommended for immunocompromised persons who completed a 3-dose primary series.
4. Includes cancer, chronic kidney disease, chronic lung disease, dementia or other neurologic conditions, diabetes, Down syndrome, heart conditions, HIV infection, immunocompromised state, liver disease, overweight or obesity, pregnancy, sickle cell disease or thalassemia, smoking (current or former), solid organ or blood stem cell transplant, stroke or cerebrovascular disease, and substance use disorders.

Booster Immunogenicity – In an unpublished longitudinal immunogenicity study (summarized in the FDA Fact Sheet), 210 adults 18-55 years old who had completed a 2-dose primary series of *Comirnaty* about 6 months previously and had no evidence of prior SARS-CoV-2 infection were given a booster dose. Geometric mean titers of anti-SARS-CoV-2 neutralizing antibodies 1 month after the booster dose were 3.29-fold higher than they were 1 month after the second primary-series dose.³

Booster Efficacy – In a one-month cohort study in ~1.1 million Israeli residents who had completed a 2-dose primary series of the Pfizer/BioNTech vaccine ≥5 months previously, persons who received a booster dose had significantly lower rates of SARS-CoV-2 infection (by 11.3-fold) and severe COVID-19 (by 19.5-fold) beginning 12 days after administration compared to those who did not.⁶

ADVERSE EFFECTS – Adverse effects with a third dose of an mRNA-based COVID-19 vaccine appear to be similar to those with the second primary-series dose.⁷ In the immunogenicity study in adults 18-55 years old, lymphadenopathy occurred more commonly with the booster dose of the Pfizer/BioNTech vaccine than with

primary-series doses (5.2% vs 0.4%), but no cases of hypersensitivity reactions, Bell's palsy, or myocarditis/pericarditis were reported in booster dose recipients.^{3,8}

OTHER VACCINES – Booster doses of the mRNA-based COVID-19 vaccine manufactured by Moderna (*Spikevax*) and the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) have not been authorized to date. The FDA and CDC are expected to consider the appropriateness of booster doses for recipients of these vaccines in the near future.

CONCLUSION – The FDA has authorized use of a single booster dose of the Pfizer/BioNTech mRNA-based COVID-19 vaccine (*Comirnaty*) administered ≥6 months after completion of the 2-dose primary series in certain adults. The efficacy of primary immunization with *Comirnaty* in preventing SARS-CoV-2 infection appears to decrease over time, especially in older persons, and administration of a booster dose has been associated with decreased rates of infection and severe COVID-19. Whether booster doses of *Comirnaty* will eventually be recommended for the general population remains to be determined. Booster doses of the Moderna and Johnson & Johnson COVID-19 vaccines are not currently recommended. ■

1. FDA News Release. FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations. September 22, 2021. Available at: <https://bit.ly/3ilp0B1>. Accessed September 30, 2021.
2. CDC. CDC statement on ACIP booster recommendations. September 24, 2021. Available at: <https://bit.ly/3o8uS42>. Accessed September 30, 2021.
3. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). September 22, 2021. Available at: <https://bit.ly/37fX1NG>. Accessed September 30, 2021.
4. SY Tartof et al. Six-month effectiveness of BNT162b2 mRNA COVID-19 vaccine in a large US integrated health system: a retrospective cohort study. 2021 August 23 (preprint). Available at: <https://bit.ly/3CJwzJ8>. Accessed September 30, 2021.
5. Y Goldberg et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. medRxiv 2021 August 30 (preprint). Available at: <https://bit.ly/2XXy4Vr>. Accessed September 30, 2021.
6. YM Bar-On et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 2021 September 15 (epub).
7. AM Hause et al. Safety monitoring of an additional dose of COVID-19 Vaccine – United States, August 12–September 19, 2021. MMWR Morb Mortal Wkly Rep 2021 September 28 (epub).
8. FDA. FDA review of effectiveness and safety of COMIRNATY (COVID-19 vaccine, mRNA) booster dose. Biologics License Application supplement. Vaccines and Related Biological Products Advisory Committee. September 17, 2021. Available at: <https://bit.ly/2ZhqsgQ>. Accessed September 30, 2021.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer. The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
 www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
 please e-mail your request to:
 permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.



Copyright 2021. ISSN 1523-2859

